Lipoprotein(a): lodestar for future clinical trials

Affiliations

¹ School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA 6847, Australia; Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, WA, Australia. Electronic address: gerald.watts@uwa.edu.au.
² Department of Biochemistry and Robarts Research Institute, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.

Comment

Gerald F Watts et al. Lancet. 2018.

. 2018 Oct 13;392(10155):1281-1282.

doi: 10.1016/S0140-6736(18)31922-6. Epub 2018 Oct 4.

¹ School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA 6847, Australia; Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, WA, Australia. Electronic address: gerald.watts@uwa.edu.au.
² Department of Biochemistry and Robarts Research Institute, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.

No abstract available

Comment on

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S. Willeit P, et al. Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293769